iBet uBet web content aggregator. Adding the entire web to your favor.

Link to original content: http://pubmed.ncbi.nlm.nih.gov/17030701/

The inflammatory hypothesis: any progress in risk stratification and therapeutic targets? - PubMed

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2006 Oct 10;114(15):1557-60.

doi: 10.1161/CIRCULATIONAHA.106.652081.

The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?

Stefan Blankenberg, Salim Yusuf

PMID: 17030701
DOI: 10.1161/CIRCULATIONAHA.106.652081

Editorial

The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?

Stefan Blankenberg et al. Circulation. 2006.

. 2006 Oct 10;114(15):1557-60.

doi: 10.1161/CIRCULATIONAHA.106.652081.

Authors

Stefan Blankenberg, Salim Yusuf

PMID: 17030701
DOI: 10.1161/CIRCULATIONAHA.106.652081

No abstract available

PubMed Disclaimer

Comment in

Letter by Ridker and Everett regarding article, "The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?".
Ridker PM, Everett BM. Ridker PM, et al. Circulation. 2007 May 22;115(20):e475; author reply e476. doi: 10.1161/CIRCULATIONAHA.106.672733. Circulation. 2007. PMID: 17515471 No abstract available.

Comment on

High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study.
Bos MJ, Schipper CM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. Bos MJ, et al. Circulation. 2006 Oct 10;114(15):1591-8. doi: 10.1161/CIRCULATIONAHA.106.619833. Epub 2006 Oct 2. Circulation. 2006. PMID: 17015791

Similar articles

[Inflammation and C-reactive protein in cardiovascular disease].
Munk PS, Larsen AI. Munk PS, et al. Tidsskr Nor Laegeforen. 2009 Jun 11;129(12):1221-4. doi: 10.4045/tidsskr.08.0011. Tidsskr Nor Laegeforen. 2009. PMID: 19521445 Review. Norwegian.
[C-reactive protein: cardiovascular issues of an acute-phase protein].
Amezcua-Guerra LM, Springall del Villar R, Bojalil Parra R. Amezcua-Guerra LM, et al. Arch Cardiol Mex. 2007 Jan-Mar;77(1):58-66. Arch Cardiol Mex. 2007. PMID: 17500194 Review. Spanish.
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group.
Smith SC Jr, Anderson JL, Cannon RO 3rd, Fadl YY, Koenig W, Libby P, Lipshultz SE, Mensah GA, Ridker PM, Rosenson R; CDC; AHA. Smith SC Jr, et al. Circulation. 2004 Dec 21;110(25):e550-3. doi: 10.1161/01.CIR.0000148981.71644.C7. Circulation. 2004. PMID: 15611380 No abstract available.
Risk assessment in the patient with established peripheral arterial disease.
Haugen S, Casserly IP, Regensteiner JG, Hiatt WR. Haugen S, et al. Vasc Med. 2007 Nov;12(4):343-50. doi: 10.1177/1358863X07083278. Vasc Med. 2007. PMID: 18048472 Review.
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
Guijarro C. Guijarro C. Circulation. 2001 Nov 27;104(22):E127. Circulation. 2001. PMID: 11723039 No abstract available.

See all similar articles

Cited by

The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry.
Sia CH, Zheng H, Ho AF, Bulluck H, Chong J, Foo D, Foo LL, Lim PZY, Liew BW, Tan HC, Yeo TC, Chua TSJ, Chan MY, Hausenloy DJ. Sia CH, et al. Sci Rep. 2020 Apr 22;10(1):6799. doi: 10.1038/s41598-020-63825-8. Sci Rep. 2020. PMID: 32321961 Free PMC article.
C-reactive protein: clinical and epidemiological perspectives.
Salazar J, Martínez MS, Chávez M, Toledo A, Añez R, Torres Y, Apruzzese V, Silva C, Rojas J, Bermúdez V. Salazar J, et al. Cardiol Res Pract. 2014;2014:605810. doi: 10.1155/2014/605810. Epub 2014 Feb 6. Cardiol Res Pract. 2014. PMID: 24653858 Free PMC article. Review.
Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease.
Ramachandran S, Venugopal A, Kutty VR, A V, G D, Chitrasree V, Mullassari A, Pratapchandran NS, Santosh KR, Pillai MR, Kartha CC. Ramachandran S, et al. Cardiovasc Diabetol. 2014 Feb 7;13:38. doi: 10.1186/1475-2840-13-38. Cardiovasc Diabetol. 2014. PMID: 24502618 Free PMC article.
Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.
Ferrari R, Fox K. Ferrari R, et al. Drugs. 2009;69(3):265-77. doi: 10.2165/00003495-200969030-00003. Drugs. 2009. PMID: 19275271 Review.
Emerging role of Toll-like receptors in atherosclerosis.
Curtiss LK, Tobias PS. Curtiss LK, et al. J Lipid Res. 2009 Apr;50 Suppl(Suppl):S340-5. doi: 10.1194/jlr.R800056-JLR200. Epub 2008 Nov 1. J Lipid Res. 2009. PMID: 18980945 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database